Drug Detail:Jentadueto (Linagliptin and metformin [ lin-a-glip-tin-and-met-for-min ])
Generic Name: LINAGLIPTIN 2.5mg, METFORMIN HYDROCHLORIDE 850mg
Dosage Form: tablet, film coated
Drug Class: Antidiabetic combinations
Drug Detail:Jentadueto (Linagliptin and metformin [ lin-a-glip-tin-and-met-for-min ])
Generic Name: LINAGLIPTIN 2.5mg, METFORMIN HYDROCHLORIDE 850mg
Dosage Form: tablet, film coated
Drug Class: Antidiabetic combinations
The dosage of JENTADUETO should be individualized on the basis of both effectiveness and tolerability, while not exceeding the maximum recommended dose of 2.5 mg linagliptin/1000 mg metformin hydrochloride (HCl) twice daily. JENTADUETO should be given twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with metformin use.
Recommended starting dose:
Assess renal function prior to initiation of JENTADUETO and periodically thereafter.
JENTADUETO is contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2.
Initiation of JENTADUETO in patients with an eGFR between 30-45 mL/min/1.73 m2 is not recommended.
In patients taking JENTADUETO whose eGFR later falls below 45 mL/min/1.73 m2, assess benefit/risk of continuing therapy.
Discontinue JENTADUETO if the patient's eGFR later falls below 30 mL/min/1.73 m2 [see Contraindications (4) and Warnings and Precautions (5.1)].
Discontinue JENTADUETO at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of liver disease, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart JENTADUETO if renal function is stable [see Warnings and Precautions (5.1)].